Trend
SBF 120 biotechs lower on 6 November 2026: Genfit falls 12%
On 6 November 2026, around midday, several French biotechs were among the biggest decliners in the SBF 120, according to Idéal Investisseur. Genfit was the hardest hit, after publishing its third-quarter results.
By Yvan T., published
The facts
According to Idéal Investisseur (published at 12:01 on 6 November 2026), Genfit was bottom of the SBF 120 with a 12% fall after its Q3. In the headline used here, the outlet does not specify the content of the results or the reasons for the sell-off.
Also according to Idéal Investisseur, Inventiva was at the same time among the biggest decliners in the index, down 4%. Valneva was near the bottom of the rankings, also down 4%, in what the outlet described as a risky session.
Nanobiotix lost 2.5% that day and showed a 12% loss over one week, according to Idéal Investisseur (11:51). For Abivax, the same outlet said the stock had broken through its support at €76.05 and was down almost 32% over three months (11:58).
These figures are intraday moves, recorded between 11:51 and 12:01. They are not closing prices, and the information available is limited to article headlines.
Our take
Our reading: the common thread between these five stocks is the sector, but their situations differ. Genfit is suffering a direct reaction to a quarterly publication. For Inventiva and Valneva, the sources give no specific cause. Nanobiotix and Abivax appear mainly for declines over one week and three months, so these are older moves than that of the session.
The risk-averse climate mentioned in the angle is supported here only by the reference to a risky session for Valneva. It remains a plausible hypothesis, as biotechs are often sensitive to market sentiment (financing needs, highly anticipated clinical results). However, it is not demonstrated by the information available.
To understand this session, we would need to know the details of Genfit’s results, any company-specific announcements and the size of the decline at the close. Without these, it is prudent not to treat these five declines as a single movement.
Risks to watch
The analysis rests solely on article headlines from a single outlet, without details of the publications or their causes. The moves cited are intraday and may have changed by the close. Biotechnology stocks remain highly volatile by nature.
Sources
- L'action Genfit lanterne rouge du SBF 120, plonge de 12 % après son T3
- L'action Inventiva parmi les plus fortes baisses du SBF 120, cède 4 %
- L'action Valneva en queue du SBF 120, repli de 4 % sur une séance à risque
- L'action Abivax enfonce son support à 76,05 € et chute de près de 32 % sur trois mois
- L'action Nanobiotix cède 2,5 % et perd 12 % en une semaine sur le SBF 120
Information from these sources is summarised and rewritten. It has not been independently verified beyond cross-checking between sources; where the reliability of a piece of information is in doubt, the article says so.
Transparency
- AuthorTo be completed, Founder and author of the site, private investor.
- Conflicts of interestThis article covers general trends. Positions held by in the stocks mentioned are disclosed on the Methodology and conflicts of interest page. The site receives no payment from the companies it covers. The author refrains from any transaction in a stock covered 24 hours before and 48 hours after publication.
- MethodCompilation of public information dated November 6, 2026 (sources listed above). The facts reported are kept separate from the analysis, which expresses the author's view. Full methodology.
- Artificial intelligenceText written with an artificial intelligence tool from the sources cited and published automatically, without prior human review.
General information, not personalised investment advice: this article does not take your situation into account. Investing in shares carries a risk of capital loss. Past performance is not a reliable indicator of future performance. Read the full risk warning.